PYK2 related products and methods
AssigneeSugen, Inc.
InventorsSima Lev, Joseph Schlessinger
Life of this patent
Estimating the term…
Abstract
The present invention features a method for treatment of an organism having a disease or condition characterized by an abnormality in a signal transduction pathway, wherein the signal transduction pathway includes a PYK2 protein. The invention also features methods for diagnosing such diseases and for screening for agents that will be useful in treating such diseases. The invention also features purified and/or isolated nucleic acid encoding a PYK2 protein.
Claims19
Isolated, purified, or enriched nucleic acid encoding a nucleic acid encoding PYK2 polypeptide.
A nucleic acid probe for the detection of nucleic acid encoding a PYK2 polypeptide in a sample.
Recombinant nucleic acid encoding a PYK2 polypeptide and a vector or a promoter effective to initiate transcription in a host cell.
Recombinant nucleic acid comprising a transcriptional region functional in a cell, a sequence complimentary to an RNA sequence encoding a PYK2 polypeptide and a transcriptional termination region functional in a cell.
An isolated, purified, recombinant, or enriched PYK2 polypeptide having a phosphorylation activity.
A purified antibody having specific binding affinity to a PYK2 polypeptide.
A hybridoma which produces an antibody having specific binding affinity to a PYK2 polypeptide.
A method of detecting a compound capable of binding to a PYK2 polypeptide comprising the steps of incubating said compound with said PYK2 polypeptide and detecting the presence of said compound bound to said PYK2 polypeptide.
A method of screening potential agents useful for treatment of a disease or condition characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway includes an interaction between a PYK2 polypeptide and a natural binding partner, comprising the step of assaying said potential agents for those able to promote or disrupt said interaction as an indication of a useful said agent.
A method for diagnosis of a disease or condition characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway includes an interaction between a PYK2 polypeptide and a natural binding partner, comprising the step of detecting the level of said interaction as an indication of said disease or condition.
A method for treatment of an organism having a disease or condition characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway includes an interaction between a PYK2 polypeptide and a natural binding partner comprising the step of promoting or disrupting said interaction.
An isolated, purified, or enriched nuclic acid sequence that:
- (a) encodes a polypeptide having the full length amino acid sequence set forth in SEQ ID NO:
- 2;
- (b) the complement of the nucleotide sequence of (a);
- (c) hybridizes under highly stringent hybridization conditions to the nucleotide sequence of (a) and encodes a naturally occurring PYK2 protein;
- (d) encodes a PYK2 protein having the full length amino acid sequence set forth on SEQ ID NO:
- 2 except that it lacks a segment of amino acid residues selected from the group consisting of:
- 1-417, 418-679, 713-733, 843-860, and 861-1009;
- (e) the complement of the nucleotide sequence of (d);
- (f) encodes a polypeptide having an amino acid sequence selected from the group cositing of amino acid residues;
- 1-417, 418-679, 713-733, 843-860, and 861-1009;
- (g) the complement of the nucleotide sequence of (f);
- (h) encodes a polypeptide having the full length amino acid sequence set forth in SEQ ID NO:
- 2 except that it lacks at least one, but not more than two, of the domains selected from the group consisting of the N-terminal domain, the kinase domain, the first protein rich domain, the second protein rich domain, and the FAT targeting domain;
- or
- (i) the complement of the nucleotide sequence of (h).
Dependencies are inferred from the claim text.